In fiscal 2023, which ended Dec 31, 2023, Panacea Life Sciences Holdings, Inc. reported revenue of $2.4 million, up 46.6% from the year before. It recorded a net loss of $8.0 million. The operating loss came to $5.5 million, an operating margin of -232.5%. Diluted earnings per share were -$0.48. Over the twelve months ended Mar 31, 2024, revenue was $2.8 million and the net loss was $7.7 million. Across the 6 fiscal years shown, revenue grew from $213 in fiscal 2015 to $2.4 million in fiscal 2023, about 545.4% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2024
Mar 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
FY 2015
Dec 31, 2015
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3
+50.4%
|
2
+46.6%
|
2
-21.0%
|
2
-77.2%
|
9
+2508.7%
|
0
|
0
|
0
|
0
-100.0%
|
0
|
| Cost of revenue |
1
-8.7%
|
1
+2.6%
|
1
-19.0%
|
2
-78.4%
|
7
+262.0%
|
2
|
—
|
—
|
—
|
—
|
| Gross profit |
2
+199.5%
|
1
+183.0%
|
0
-26.7%
|
1
-72.9%
|
2
+217.5%
|
-2
|
—
|
—
|
—
|
—
|
| Research and development |
—
|
—
|
—
|
—
|
0
-100.0%
|
0
-92.6%
|
0
-15.7%
|
0
-3.6%
|
0
+377.5%
|
0
|
| Selling, general and administrative |
1
+62.7%
|
1
+33.2%
|
1
-28.0%
|
2
-55.9%
|
3
-8.5%
|
4
+96.6%
|
2
+57.0%
|
1
+60.6%
|
1
+600.3%
|
0
|
| Operating income |
-5
-0.4%
|
-6
+1.9%
|
-6
+4.8%
|
-6
-12.9%
|
-5
+50.7%
|
-11
-338.1%
|
-2
+22.0%
|
-3
-95.1%
|
-2
-311.4%
|
-0
|
| Other income (expense) |
-2
+17.5%
|
-2
+29.3%
|
-3
-402.3%
|
1
|
—
|
—
|
—
|
—
|
—
|
—
|
| Pretax income |
-8
+5.9%
|
-8
+12.3%
|
-9
-91.2%
|
-5
+8.6%
|
-5
+47.8%
|
-10
-131.0%
|
-4
-12.3%
|
-4
-140.8%
|
-2
-347.5%
|
-0
|
| Income tax |
—
|
—
|
—
|
—
|
—
|
—
|
0
|
0
|
0
|
—
|
| Net income |
-8
+5.9%
|
-8
+12.3%
|
-9
-91.2%
|
-5
+8.6%
|
-5
+47.8%
|
-10
-131.0%
|
-4
-12.3%
|
-4
-140.8%
|
-2
-347.8%
|
-0
|
| Basic EPS |
-0.45
+20.4%
|
-0.48
+22.6%
|
-0.62
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Diluted EPS |
—
|
-0.48
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
17
+18.2%
|
17
+11.9%
|
15
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, diluted |
—
|
17
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Other measures | ||||||||||
| Depreciation and amortization |
2
-0.6%
|
2
+2.6%
|
2
-0.4%
|
2
+2.8%
|
2
+2457.0%
|
0
|
—
|
—
|
0
-100.0%
|
0
|
| EBITDA |
-4
-0.8%
|
-4
+3.8%
|
-4
+6.5%
|
-4
-17.5%
|
-4
+65.8%
|
-11
|
—
|
—
|
-2
-313.1%
|
-0
|
| Interest coverage |
-3.31x
|
-3.56x
|
-2.76x
|
-5.37x
|
-3.48x
|
-22.28x
|
-5.25x
|
-45.57x
|
—
|
—
|
| Margins | ||||||||||
| Gross margin |
56.53%
|
47.04%
|
24.37%
|
26.25%
|
22.15%
|
-491.92%
|
—
|
—
|
—
|
—
|
| Operating margin |
-192.25%
|
-232.55%
|
-347.41%
|
-288.26%
|
-58.31%
|
-3,087.46%
|
—
|
—
|
—
|
-182,761.50%
|
| Pretax margin |
-277.51%
|
-336.08%
|
-561.94%
|
-232.20%
|
-58.02%
|
-2,898.29%
|
—
|
—
|
—
|
-168,164.32%
|
| Profit margin |
-277.51%
|
-336.08%
|
-561.94%
|
-232.20%
|
-58.02%
|
-2,898.29%
|
—
|
—
|
—
|
-168,064.32%
|
| EBITDA margin |
-131.68%
|
-160.72%
|
-244.78%
|
-206.90%
|
-40.22%
|
-3,069.02%
|
—
|
—
|
—
|
-181,997.65%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- PLSH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Greenwood Village, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1552189
- Former names
- Exactus, Inc. (until Oct 26, 2021); Spiral Energy Tech., Inc. (until Mar 4, 2016); Solid Solar Energy, Inc. (until Aug 7, 2013)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.